Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: William J. Leiby who wrote (567)	2/17/1998 6:21:00 PM
From: John McCarthy	Read Replies (2) \| Respond to of 849

Hi Bill - OK - I admit it. Whats up with the letter of intent verbage below? Are we launching an air strike or something? Thanks and Regards, John Snippet of P&L Release from today: ================================================================== 'The letter of intent which we have signed with a recognized leader in the distribution of diagnostic products to clinical laboratories is further testament to the clinical potential of the NMP22(R) Test Kit,'' said David L. Corbet, President of Matritech. ''Matritech's strategy for building market acceptance of the NMP22(R) Test Kit includes targeting key thought leaders in the field, securing partners for automated systems for testing, expanding U.S. distribution and by continuing to use our dedicated sales force and educational programs to broadly reach urologists. We continue to increase acceptance for NMP22(R)) with thought leading institutions such as New York University Medical Center, Boston Medical Center and University of California, Irvine, and in strengthening distribution channels in Europe and the U.S.''